Relationships between adipose tissue and psoriasis, with or without arthritis

Frontiers in Immunology

Volumn 5, Issue AUG, 2014, Pages

  Toussirot, Éric ^a,b,c,d   Aubin, François ^a,b   Dumoulin, Gilles ^a,e  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c Hôpital Saint Jacques   (France)

^d UPRES EA 4266 Pathogens and Inflammation University of Franche Comté ^*  (France)

^e Bâtiment Socrate   (France)

Author keywords

Adipokines; Cardiovascular risk; Obesity; Psoriasis; Psoriatic arthritis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ADIPOSE TISSUE; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR RISK; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY BALANCE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LOW CALORY DIET; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN;

EID: 84924020511     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00368     Document Type: Review

References (56)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med (2009) 361:496-509. doi:10.1056/NEJMra0804595
2. Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. Am JMed (2009) 122(1150):e1-9. doi:10.1016/j.amjmed.2009.06.021
3. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis (2011) 70(Suppl 1):i77-84. doi:10.1136/ard.2010. 140582
4. Wilson FC, Icen M, Crowson CS, Mc Evoy MT, Gabriel SE, Kremers HM. Inci-dence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population based study. Arthritis Rheum (2009) 61:233-9. doi:10.1002/art. 24172
5. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum (2006) 54:2665-73. doi:10.1002/art.21972
6. Canete JD, Mease P. The link between obesity and psoriatic arthritis. Ann Rheum Dis (2012) 71:1265-6. doi:10.1136/annrheumdis-2012-201632
7. Papoutsaki M, Costanzo A. Treatment of psoriasis and psoriatic arthritis. BioDrugs (2013) 27(Suppl 1):3-12. doi:10.1007/BF03325638
8. Hercogova J, Ricceri F, Tripo L, Lotti T, Prignano F. Psoriasis and body mass index. Dermatol Ther (2010) 23:152-4. doi:10.1111/j.1529-8019.2010.01309.x
9. Toussirot E, Streit G, Wendling D. The contribution of adipose tissue and adipokines to infiammation in joint diseases. Curr Med Chem (2007) 14:1095-100. doi:10.2174/092986707780362826
10. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol (2006) 126:2194-201. doi:10.1038/sj.jid.5700410
11. Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, et al. Risk of cancer in psoriasis: a systematic review and meta analysis of epi-demiological studies. J Eur Acad Dermatol Venereol (2013) 27(Suppl 3):36-46. doi:10.1111/jdv.12165
12. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA (2006) 296:1735-41. doi:10.1001/jama.296.14.1735
13. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case control analysis. Br J Dermatol (2009) 160:1048-56. doi:10.1111/j.1365-2133.2008.09020.x
14. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol (1995) 32:982-6. doi:10.1016/0190-9622(95)91336-X
15. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe pso-riasis. Arch Dermatol Res (2006) 298:321-8. doi:10.1007/s00403-006-0703-z
16. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. JAm Acad Dermatol (2006) 54:614-21. doi:10.1016/j.jaad.2005.11.1079
17. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol (2006) 55:829-35. doi:10.1016/j.jaad.2006.08.040
18. Third report of the national cholesterol education program(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment phase III) final report. Circulation (2002) 106: 3143-421. Available from: http://circ.ahajournals.org/content/106/25/3143.citation
19. Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol (2013) 27(Suppl 3):12-29. doi:10.1111/jdv.12163
20. Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) (2013) 52:62-7. doi:10.1093/rheumatology/ kes242
21. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord (2010) 8:331-4. doi:10.1089/met.2009.0124
22. Jamnitski A, Symmons D, Peters MJ, Sattar N, Mc Innes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis (2013) 72:211-6. doi:10.1136/annrheumdis-2011-201194
23. Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) (2011) 63:1729-35. doi:10.1002/acr.20627
24. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol (2005) 125:61-7. doi:10.1111/j.0022-202X.2005.23681.x
25. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation andmanagement.Arch Dermatol (2005) 141:1527-34. doi:10.1001/archderm.141.12.1527
26. Setty AR, Curhan G, Choi HK. Obesity,waist circumference,weight change, and the risk of psoriasis in women: Nurses'Health Study II. Arch Intern Med (2007) 167:1670-5. doi:10.1001/archinte.167.15.1670
27. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol (2007) 143:1559-65. doi:10.1001/archderm. 143.12.1559
28. Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol (2010) 146:721-6. doi:10.1001/archdermatol.2010.141
29. Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, et al. Obesity and the risk of psoriatic arthritis: a population based study. Ann Rheum Dis (2012) 71:1273-7. doi:10.1136/annrheumdis-2012-201299
30. Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis (2012) 71:1267-72. doi:10.1136/annrheumdis-2011-201273
31. Paller AS, Mercy K, Kwasny MJ, Choon SE, Cordoro KM, Girolomoni G, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol (2013) 149:166-76. doi:10.1001/jamadermatol.2013.1078
32. Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arthritis Res Ther (2011) 13:R16. doi:10.1186/ar3240
33. Toussirot E, Binda D, Gueugnon C, Dumoulin G. Adiponectin in autoimmune diseases. Curr Med Chem (2012) 19:5474-80. doi:10.2174/092986712803833119
34. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol (2011) 20:81-7. doi:10.1111/j.1600-0625.2010.01210.x
35. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol (2008) 159:1364-7. doi:10.1111/j.1365-2133.2008. 08759.x
36. Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci (2009) 55:62-3. doi:10.1016/j.jdermsci.2009.02.009
37. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol (2008) 158:1134-5. doi:10.1111/j.1365-2133.2008.08456.x
38. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, Ergun T. Serumleptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol (2008) 159:820-6. doi:10.1111/j.1365-2133.2008.08742.x
39. Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnars-son SI, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous infiammation. Br JDermatol (2008) 159:342-50. doi:10.1111/j.1365-2133.2008. 08655.x
40. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, Krentz H, et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol (2005) 15:251-7.
41. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 354:2552-63. doi:10.1056/ NEJMoa054862
42. Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowi-etz U. Leptin, adiponectin, visfatin and retinol-binding protein-4 -media-tors of comorbidities in patients with psoriasis? Exp Dermatol (2012) 21:43-7. doi:10.1111/j.1600-0625.2011.01402.x
43. Ismail SA, Mohamed SA. Serumlevels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. Br J Dermatol (2012) 167:436-9. doi:10.1111/j.1365-2133.2012.10980.x
44. Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis (2013) 72:1956-61. doi:10.1136/annrheumdis-2012-202325
45. Xue Y, Jiang L, Cheng Q, Chen H, Yu Y, Lin Y, et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One (2012) 7:e46740. doi:10.1371/journal.pone.0046740
46. Toussirot E, Mourot L, Dehecq B, Wendling D, Grandclement E, Dumoulin G. TNFalpha blockade for infiammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. Eur J Nutr (2014) 53:951-61. doi:10.1007/s00394-013-0599-2
47. Renzo LD, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment. Dermatol Ther (2011) 24:446-51. doi:10.1111/j.1529-8019.2011.01439.x
48. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol (2008) 22:341-4. doi:10.1111/j.1468-3083.2007.02429.x
49. Prignano F, Ricceri F, Pescitelli L, Buggiani G, Troiano M, Zanieri F, et al. Com-parison of body weight and clinical-parameter changes following the treat-ment of plaque psoriasis with biological therapies. Curr Med Res Opin (2009) 25:2311-6. doi:10.1185/03007990903162465
50. Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol (2013) 168:1124-7. doi:10.1111/bjd.12235
51. Hossler EW, Maroon MS, Mowad CM. Gastric bypass surgery improves psoriasis. J Am Acad Dermatol (2011) 65:198-200. doi:10.1016/j.jaad.2010.01.001
52. Puig L. Obesity and psoriasis: body weight and body mass index infiuence the response to biological treatment. J Eur Acad Dermatol Venereol (2011) 25:1007-11. doi:10.1111/j.1468-3083.2011.04065.x
53. di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) (2013) 65:141-7. doi:10.1002/acr.21711
54. Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R.Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers. Ann Rheum Dis (2014) 73:1157-62. doi:10.1136/annrheumdis-2012-202812
55. Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis (2014). doi:10.1136/annrheumdis-2013-204448
56. Bhole VM, Choi HK, Burns LC, Vera Kellet C, Lacaille DV, Gladman DD, et al. Differences in body mass index among individuals with Ps A, psoriasis, RA and the general population. Rheumatology (Oxford) (2012) 51:552-6. doi:10.1093/rheumatology/ker349